Actelion Ltd.'s 2007 acquisition of CoTherix, Inc. has just gotten more expensive. The Allschwil, Switzerland-based firm is cutting about $80 million from its operating profit forecast for 2009, following a decision by an arbitration panel that it should pay $91 million, plus interest, to Asahi Kasei Pharma Corp. arising out of a termination of a drug development alliance involving CoTherix. (BioWorld International) Read More
